

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.27%
+0.61%
+3.26%
-10.82%
-8.09%
MRUS
Merus N.V. h
$94.94
Strengths

Earnings are forecast to grow
Risk Analysis

Downgraded on weak valued

Investors losing their confidence
Chart
$68.89 (+37.81%)
$67.05 (+41.60%)
$62.42 (+52.10%)
$53.13 (+78.69%)
MRUS has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

MRUS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Downgraded on weak valued
Momentum
Momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow
![]()
MRUS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MRUS Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayMRUS Earnings
The TTM reflects 12-month period, providing review of MRUS financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
MRK
87.69
+0.56%
XNCR
13.33
+8.02%
VSTM
8.14
+4.35%
SNY
51.67
+4.33%
PFE
24.75
+0.20%
What is MRUS current stock price?
What are MRUS stock strengths?
What risks are associated with MRUS stock?
When is MRUS next earnings report?
What is MRUS market cap and volume?
What is MRUS's current Stock IQ?
Should I buy MRUS stock right now?
Is MRUS a Strong Buy right now?
What does a 'Strong Buy' rating mean for MRUS?
What does a 'Strong Sell' rating mean for MRUS?
What factors influence MRUS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.27%
+0.61%
+3.26%
-10.82%
-8.09%
MRUS
Merus N.V. h
Current Price
$94.94
Stock Insights
Strengths

Earnings are forecast to grow
Risk Analysis

Downgraded on weak valued

Investors losing their confidence
Linked to MRUS
MRK
87.69
+0.56%
XNCR
13.33
+8.02%
VSTM
8.14
+4.35%
SNY
51.67
+4.33%
PFE
24.75
+0.20%
Chart
$68.89 (+37.81%)
$67.05 (+41.60%)
$62.42 (+52.10%)
$53.13 (+78.69%)
MRUS Analysts Opinion
MRUS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Downgraded on weak valued
Momentum
Momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow
![]()
MRUS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MRUS Street view is extremely bullish and have negative views on the near-term outlook
MRUS has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels.
MRUS Earnings
The TTM data reflects the most recent 12-month period, providing overview of MRUS financial performance.
MRUS Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
MRUS Latest Analysis
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. - Plenary session oral presentation: Friday October 24 10:00 -11:40 a.m. ET
Mon Oct 13, 2025
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal. Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Mon Oct 6, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MRUS Stock trends
MRUS Stock performance
MRUS Stock analysis
MRUS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.